24 related articles for article (PubMed ID: 10719738)
1. Association of MDM2 Overexpression in Ameloblastomas with
Tosios KI; Kalogirou EM; Koutlas IG
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916
[TBL] [Abstract][Full Text] [Related]
2. MiR-205-5p Functions as a Tumor Suppressor in Gastric Cancer Cells through Downregulating FAM84B.
Chen X; Zhang L; Geng J; Chen Z; Cui X
J Oncol; 2022; 2022():8267891. PubMed ID: 35669244
[TBL] [Abstract][Full Text] [Related]
3. Expression of MDM2 mRNA, MDM2, P53 and P16 Proteins in Urothelial Lesions in the View of the WHO 4
Hammam O; Magdy M; Badawy M; Osili KA; Kholy AE; LeitHy TE
Open Access Maced J Med Sci; 2017 Aug; 5(5):578-586. PubMed ID: 28932295
[TBL] [Abstract][Full Text] [Related]
4. Phosphatidylinositol 3'-kinase, mTOR, and glycogen synthase kinase-3β mediated regulation of p21 in human urothelial carcinoma cells.
Yohn NL; Bingaman CN; DuMont AL; Yoo LI
BMC Urol; 2011 Aug; 11():19. PubMed ID: 21864408
[TBL] [Abstract][Full Text] [Related]
5. Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma.
Jahnson S; Karlsson MG
Cancer; 2000 Aug; 89(3):619-29. PubMed ID: 10931462
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
[TBL] [Abstract][Full Text] [Related]
7. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C
Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716
[TBL] [Abstract][Full Text] [Related]
8. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
[TBL] [Abstract][Full Text] [Related]
9. P21/waf1 protein expression in nasopharyngeal carcinoma. Comparative study with PCNA, p53 and MDM-2 protein expression.
Kouvidou C; Stefanaki K; Dai Y; Tzardi M; Koutsoubi K; Darivianaki K; Karidi E; Rontogianni D; Zois E; Kakolyris S; Georgoulias V; Delides G; Kanavaros P
Anticancer Res; 1997; 17(4A):2615-9. PubMed ID: 9252690
[TBL] [Abstract][Full Text] [Related]
10. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.
Pfister C; Larue H; Moore L; Lacombe L; Veilleux C; Tetu B; Meyer F; Fradet Y
Int J Cancer; 2000 Jan; 89(1):100-4. PubMed ID: 10719738
[TBL] [Abstract][Full Text] [Related]
11. p53 and p53-regulated genes in bladder cancer.
Keegan PE; Lunec J; Neal DE
Br J Urol; 1998 Nov; 82(5):710-20. PubMed ID: 9839588
[No Abstract] [Full Text] [Related]
12. Tp53 and its potential therapeutic role as a target in bladder cancer.
Ciccarese C; Massari F; Blanca A; Tortora G; Montironi R; Cheng L; Scarpelli M; Raspollini MR; Vau N; Fonseca J; Lopez-Beltran A
Expert Opin Ther Targets; 2017 Apr; 21(4):401-414. PubMed ID: 28281901
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
